When was Seragon founded?

Seragon was founded in 2005 and raised its 1st funding round 8 years after it was founded.

Where is Seragon located?

Seragon is headquartered in Irvine, United States.

Who is the current CEO of Seragon?

Carlos Arazati of Seragon. They have also founded 1 company.

How many employees does Seragon have?

As of Apr 30, 2026, the latest employee count at Seragon is 11.

Is Seragon a funded company?

Seragon is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Oct 16, 2013.

When was the latest funding round of Seragon?

Seragon's latest funding was a $***** Series A round on Oct 16, 2013, with participation from 5 investors.

Where does Seragon rank among its competitors?

Seragon ranks 47th amongst 417 active competitors, of which 85 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was SeqOne, which secured $22.7M in May, 2025.

Who are the top competitors of Seragon?

Seragon's top competitors include Benchling, Helix and Formation Bio. Among them, SeqOne secured the most recent funding round in May, 2025.

Seragon - 2026 Company Profile, Team, Funding & Competitors

Seragon is a series A company based in Irvine (United States), founded in 2005 by Carlos Arazati. It operates as a Provider of AI-based platform for epigenetics and transcriptomics for treating aging and physiological disorders. Seragon has raised $30M in funding. The company has 417 active competitors, including 85 funded and 36 that have exited. Its top competitors include companies like Benchling, Helix and Formation Bio.

Company Details

Seragon Pharmaceuticals AI-based platform for epigenetics and transcriptomics for treating aging and physiological disorders. The company offers the solution for biopharmaceutical research like biomedical design and therapeutics manufacturing for metabolic, gene therapy, and immunology for both animals and humans. The company offers databases collected after research on human genomes, and by using machine learning algorithms it can identify markers of gene expression and compare it with an individual’s genome which helps in identifying early symptoms of homeostasis or metabolic conditions.

Website: www.seragon.com/
Email ID: *****@seragon.com

Key Metrics

Founded Year

2005

Location

Irvine, United States

Stage

Series A

Total Funding

$30M in 1 round

Latest Funding Round

Series A, Oct 16, 2013, $*****

Investors

Orbimed & 4 more

Ranked

47^th among 417 active competitors

Employee Count

11 as on Apr 30, 2026

Similar Companies

Benchling & 580 more

View Seragon's full profile

Seragon is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Seragon Pharmaceuticals CIN: 463103525 , United States, Active	Dec 31, 2004	-	25 (As on Dec 31, 2014)	-

Seragon has raised a total funding of $30M over 1 round. Its latest funding round was a Series A round on Oct 16, 2013 for $*****. 5 investors participated in its latest round. Seragon has 5 institutional investors.

Here is the list of recent funding rounds of Seragon:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 16, 2013	6135966	Series A	9831221	8791947	8307325	4313311

Access funding benchmarks and valuations. Sign up today!

View details of Seragon's funding rounds and investors

The founders of Seragon is Carlos Arazati. Carlos Arazati is the CEO of Seragon.

Here are the details of Seragon's key team members:

Carlos Arazati: Founder & CEO of Seragon.

View details of Seragon's Founder profiles and Board Members

Seragon's employee count trend

Seragon has 11 employees as of Apr 26. Here is Seragon's employee count trend over the years:

Uncover Seragon's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Seragon include Benchling, Helix and Formation Bio. Here is the list of Top 10 competitors of Seragon, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Benchling 2012, San Francisco (United States), Series F	Provider of a cloud-based bioinformatics platform for biotech research	$412M	Altimeter Capital, Sequoia Capital & 28 others	73/100
2nd	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
3rd	Formation Bio 2016, New York City (United States), Series D	Provider of AI-powered drug discovery platform for various diseases	$608M	Sequoia Capital, Andreessen Horowitz & 16 others	70/100
4th	Congenica 2013, Cambridge (United Kingdom), Acquired	Developer of software for clinical genomic interpretation and variant analysis	$81.9M	IDO Investments, Puhua Capital & 39 others	62/100
5th	Cellarity 2015, Cambridge (United States), Series C	AI-powered drug design and development platform	$294M	Pictet Group, BlackRock & 5 others	62/100
6th	Latch 2021, San Francisco (United States), Series A	Provider of a web-based platform for genomic bioinformatics	$33M	Lux Capital, Coatue & 7 others	59/100
7th	deCODE Genetics 1996, Reykjavik (Iceland), Acquired	Provider of a bioinformatics platform for genetic analysis	-	Hercules Capital, Tekla Capital Management ... & 10 others	58/100
8th	SeqOne 2017, Montpellier (France), Series A	Provider of bioinformatics tools for the analysis of genome sequencing data	$48.8M	Elaia, Supernova Invest & 7 others	58/100
9th	BostonGene 2015, Waltham (United States), Series B	Developer of cloud-based information and analytics platform to treat cancer	$200M	NEC, Japan Industrial Partners & 1 others	57/100
10th	NextBio 2004, Santa Clara (United States), Acqui-Hired	NextBio provides a platform to aggregate and interpret large quantities of genomic data for research and clinical applications.	$28.3M	Rising Tide Fund, RONA Holdings & 6 others	56/100
47th	Seragon 2005, Irvine (United States), Series A	Provider of AI-based platform for epigenetics and transcriptomics for treating aging and physiological disorders	$30M	Orbimed, The Column Group & 3 others	39/100